Clinical Trials in the Category "Gastrointestinal Neoplasms"
Drug Intervention Trials that are Recruiting
Study Title |
Principal Investigator | Disease Category | |
 |
|||
| Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients |
George Albert Fisher M.D. Ph.D. |
Gastrointestinal Stromal Tumors | |
|
|||
| Phase I Vandetanib plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer |
Branimir I Sikic |
Colorectal Neoplasms
Anal, Colon, and Rectal Cancers | |
|
|||
| A Phase II Study of GSK1363089 (Formerly XL880) for Metastatic Gastric Cancer |
James M Ford |
Stomach Cancer | |
|
|||
| Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project |
Dr Andrew Quon |
Colorectal Neoplasms
Anal, Colon, and Rectal Cancers | |
|
|||
| Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer |
Dr Andrew Shelton |
Rectal Cancer
Colorectal Neoplasms Anal, Colon, and Rectal Cancers | |
|
|||
| Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma |
George Albert Fisher M.D. Ph.D. |
Stomach Cancer | |
|
|||
Other Trials that are Recruiting
| Study Title |
Principal Investigator | Disease Category | |
|
|||
| Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors |
Kate R Lorig |
Breast Cancer
Prostatic Neoplasms Colorectal Neoplasms Anal, Colon, and Rectal Cancers Blood Cancer | |
|
|||
| Clinical and Pathologic Studies of Patients Undergoing Treatment with EGFR Inhibitors |
George Albert Fisher M.D. Ph.D. Russell Pachynski |
Head and Neck Cancer
Colorectal Neoplasms Anal, Colon, and Rectal Cancers Colonic Neoplasms Lung Cancer Colon Cancer | |
|
|||
| Permission to Collect Blood over Time for Research |
Haruka Itakura |
Gastrointestinal Neoplasms
Pancreatic Cancer | |
|
|||
| Molecular Genetic and Pathological Studies of Anal Tumors |
Mark Lane Welton |
Rectal Cancer
Anal Cancer Colonic Neoplasms Colon Cancer | |
|
|||
| Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer |
Mark Lane Welton |
Rectal Cancer | |
|
|||
| QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT |
Mark Lane Welton |
Anal Cancer | |
|
|||
| Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample |
Irene L. Wapnir |
Breast Cancer
Salivary Gland Neoplasms Stomach Cancer Thyroid Cancer | |
|
|||
Trials not Recruiting
| Study Title |
Principal Investigator | Disease Category | |
|
|||
|
Safety Study of Cetuximab in combination with Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
(Completed) |
George Albert Fisher M.D. Ph.D. Branimir I Sikic |
Rectal Cancer | |
|
|||
|
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
(No longer recruiting) |
Daniel T Chang |
Esophageal Neoplasms
Adenocarcinoma Carcinoma, Squamous Cell | |
|
|||
|
Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA
(Terminated) |
Albert Koong |
Rectal Cancer | |
|
|||
|
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
(Suspended) |
Harlan Pinto |
Colonic Neoplasms
Colon Cancer | |
|
|||
| The physicians of the Stanford Cancer Center are engaged in more than 250 clinical trials. Contracts with some of our clinical trial sponsors prevent us from listing specific trial information on our web site. Please contact the Stanford Cancer Clinical Trials Office at 650-498-7061 for information about additional open clinical trials. |
Trial Administration